8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Mar 23, 2026·SEC
Intelligent Bio Solutions Inc.(INBS)Earnings, Financials & Key Ratios
INBS•NASDAQ
$2.25
Price updated Jun 27, 2026
AboutIntelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Show more
- Revenue$3M-1.9%
- EBITDA-$10M-3.9%
- Net Income-$11M-4.1%
- EPS (Diluted)-20.00+68.7%
- Gross Margin40.85%-10.8%
- EBITDA Margin-316.93%-5.9%
- Operating Margin-348.71%-5.5%
- Net Margin-346.23%-6.1%
- ROE-192.21%-12.3%
INBS Price & Volume
Intelligent Bio Solutions Inc. (INBS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Obscure Revenue Growth Potential
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"Intelligent Bio Solutions faces a challenging fundamental outlook characterized by extreme revenue volatility and a structural inability to achieve positive free cash flow, which has consistently remained negative over the last ten quarters. While the company reported a 45.5% year-over-year revenue increase in 2026Q3, this growth is undermined by SG&A expenses that frequently exceed $2.5M per quarter, far outpacing top-line generation. Investors should remain cautious as the firm's reliance on external capital and the presence of $3.0M in goodwill on the balance sheet suggest significant risks to long-term operational viability."
Verdict Logic
the company's inability to generate positive free cash flow and its reliance on external funding, evidenced by a $4.5M cash outflow in 2026Q3, present substantial risks to shareholder value.
INBS Growth Metrics
Intelligent Bio Solutions Inc. (INBS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years74.48%
3 Years-
TTM33.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-13.16%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM63.07%
Return on Capital
10 Years-287.15%
5 Years-141.59%
3 Years-185.82%
Last Year-189.63%
INBS Recent Earnings
Intelligent Bio Solutions Inc. (INBS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$1.80-228.6%
$1.40
Rev
$1M-85.3%
$7M
Q2 2026
May 12, 2026Metric
Actual
Est
EPS
$1.80-228.6%
$1.40
Rev
$1M-85.3%
$7M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$2.82-805.0%
$0.40
Rev
$896,774-83.7%
$6M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$3.50-133.3%
$1.50
Rev
$1M-76.8%
$5M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.80vs $1.40-228.6% | $1Mvs $7M-85.3% |
| Q2 2026 | May 12, 2026 | $1.80vs $1.40-228.6% | $1Mvs $7M-85.3% |
| Q1 2026 | Feb 12, 2026 | $2.82vs $0.40-805.0% | $896,774vs $6M-83.7% |
| Q4 2025 | Nov 12, 2025 | $3.50vs $1.50-133.3% | $1Mvs $5M-76.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Intelligent Bio Solutions Inc. (INBS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.25 | $1.45M | -0.11 | -1.9% | -346.23% | -192.21% | — | |
| $5.12 | $96.08M | 18.96 | 18.78% | 6.37% | 5.47% | — | |
| $13.79 | $938.85M | -0.83 | -1.89% | -45.57% | -56.31% | — | |
| $25.39 | $66.72M | -3.02 | 195.75% | -59.65% | -98.3% | — | |
| $1.66 | $91.27M | -1.30 | 15.57% | -468.74% | -26.58% | — | |
| $551.50 | $43.8B | 42.16 | 10.42% | 24.63% | 70.87% | — |
Compare INBS vs Peers
Intelligent Bio Solutions Inc. (INBS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INBS SEC Filings & Documents
Intelligent Bio Solutions Inc. (INBS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when INBS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INBS Frequently Asked Questions
Intelligent Bio Solutions Inc. (INBS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Intelligent Bio Solutions Inc.'s revenue?
Intelligent Bio Solutions Inc. (INBS) reported $3.9M in revenue for fiscal year 2025.
How fast is Intelligent Bio Solutions Inc. growing?
Intelligent Bio Solutions Inc. (INBS) saw revenue decline by 1.9% over the past year.
Is INBS profitable?
Intelligent Bio Solutions Inc. (INBS) reported a net loss of $11.6M for fiscal year 2025.
Dividend & Returns
What is INBS's return on equity?
Intelligent Bio Solutions Inc. (INBS) has a return on equity (ROE) of -192.2%. Negative ROE indicates the company is unprofitable.
What is Intelligent Bio Solutions Inc.'s free cash flow?
Intelligent Bio Solutions Inc. (INBS) had negative free cash flow of $11.4M in fiscal year 2025, likely due to heavy capital investments.